| Company Name: |
3B Pharmachem (Wuhan) International Co.,Ltd.
|
| Tel: |
18930552037 |
| Email: |
3bsc@sina.com |
| Products Intro: |
Product Name:CCT 018159;4-[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-5-Methyl-1H-pyrazol-3-yl]-6-ethyl-1,3-benzenediol
CAS:171009-07-7
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
|
CCT 018159 manufacturers
- CCT018159
-
- $31.00
-
2026-06-02
- CAS:171009-07-7
- Purity: 99.79%
- Supply Ability: 10g
|
| | CCT 018159 Basic information |
| Product Name: | CCT 018159 | | Synonyms: | CCT 018159;4-[4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl]-6-ethyl-1,3-benzenediol;HSP90 Inhibitor, CCT018159 - CAS 171009-07-7 - Calbiochem;1,3-Benzenediol, 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methyl-1H-pyrazol-3-yl]-6-ethyl-;4-(4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-5-methyl-1H-pyrazol-3-yl)-6-ethylbenzene-1,3-diol;CCT 018159, Hsp90 ATPase inhibitor | | CAS: | 171009-07-7 | | MF: | C20H20N2O4 | | MW: | 352.38 | | EINECS: | | | Product Categories: | | | Mol File: | 171009-07-7.mol |  |
| | CCT 018159 Chemical Properties |
| Boiling point | 547.3±50.0 °C(Predicted) | | density | 1.322±0.06 g/cm3(Predicted) | | storage temp. | Store at +4°C | | solubility | ≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide | | pka | 8.84±0.48(Predicted) | | form | White solid | | color | White to off-white | | Water Solubility | water: 1.7mg/mL
DMSO: 35mg/mL
ethanol: 35mg/mL | | InChI | 1S/C20H20N2O4/c1-3-12-8-14(16(24)10-15(12)23)20-19(11(2)21-22-20)13-4-5-17-18(9-13)26-7-6-25-17/h4-5,8-10,23-24H,3,6-7H2,1-2H3,(H,21,22) | | InChIKey | OWPMENVYXDJDOW-UHFFFAOYSA-N | | SMILES | [nH]1nc(c(c1C)c3cc4c(cc3)OCCO4)c2c(cc(c(c2)CC)O)O |
| WGK Germany | WGK 2 | | Storage Class | 11 - Combustible Solids |
| | CCT 018159 Usage And Synthesis |
| Uses | CCT 018159 is a cell-permeable compound that inhibits Hsp90 ATPase. | | Definition | ChEBI: A member of the class of pyrazoles that is 1H-pyrazole carrying 1,4-benzodioxane-6-yl and 5-ethyl-2,4-dihydroxyphenyl substituents at positions 4 and 5 respectively. | | Biological Activity | Novel inhibitor of heat shock protein 90 (Hsp90) ATPase activity (IC 50 = 5.7 μ M) that displays selectivity over human Hsp72 and topoisomerase II. Inhibits proliferation of HCT116 human colon tumor cells and produces upregulation of Hsp70 and downregulation of c-Raf and cdk4. More soluble than 17-AAG (17-Demethoxy-17-(2-propenylamino)geldanamycin ) and is independent of NQO1/DT-diaphorase and P-glycoprotein expression. | | in vitro | cct018159 was identified by high-throughput screening inhibiting human hsp90beta with comparable potency to 17-aag and with similar atp-competitive kinetics. x-ray crystallographic structures of the yeast hsp90 complexed with cct018159 showed binding properties similar to radicicol. the mean cellular gi50 of cct018159 across a panel of human cancer cell lines, including melanoma, was 5.3 μm. unlike 17-aag, the in-vitro antitumor activity of cct018159 was independent of nqo1/dt-diaphorase and p-glycoprotein expression. the signature of hsp90 inhibition, comprising increased expression of hsp72 protein and depletion of erbb2, cdk4, c-raf, and mutant b-raf, was indicated in human cancer cell lines treated with cct018159 [1]. | | in vivo | in human tumor xenografts including skmel 28 melanoma cells, cct018159 was found to induce the expression of hsp72 as well as erbb2, cdk4 and dc-raf [1]. | | IC 50 | 3.2 and 6.6 μm for human hsp90β and yeast hsp90, respectively | | storage | Store at +4°C | | references | [1] s. y. sharp, k. boxall, m. rowlands, et al. in vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. cancer research 67(5), 2206-2216 (2007). |
| | CCT 018159 Preparation Products And Raw materials |
|